Porównaj metody

	Oznaczenie hemolizy	CAM Assay
Dziedzina	Biomateriały	Biomateriały
Rodzina	Process / pipeline	Process / pipeline
Rok powstania	1950	1974
Twórca	Clinical hematology traditions	Judah Folkman
Typ	Hemolytic compatibility assay	Developmental biology assay
Źródło pierwotne	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.
Inne nazwy	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model
Pokrewne	4	4
Podsumowanie	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.